Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?

Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target? is a pharma and life sciences industry update from PharmaVoice. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Kelly Bilodeau · 2026-06-04

While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.

Source: PharmaVoice